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Background- Dysregulation of 
mammalian target of rapamycin (mTOR) 
signaling has been found in many 
human tumors, including endometrial 
cancer, and mTOR inhibitors have been 
utilized in clinical trials as targeted 
therapies. Although the mTORC1 
inhibitor temsirolimus initially exhibited 
broad antitumor activity in preclinical 
models and Phase II/III clinical trials, 
many patients do not respond to therapy 
and relapse is common.  Several 
resistance mechanisms have been 
hypothesized, including an increase in 
AKT phosphorylation after treatment 
with temsirolimus and subsequent 
activation of AKT-dependent pro-
survival pathways. 
Hypothesis and Approach - In order to 
identify a viable treatment alternative 
that overcomes temsirolimus-induced 
AKT phosphorylation in endometrial 
cancer, we assessed the therapeutic 
benefit of dual mTOR/PI3K inhibition 
using a panel of endometrial cancer cell 
lines.  
Results - Of the six drugs tested, NVP-
BEZ235 (dual PI3K/mTOR inhibitor) and 
ZSTK474 (PI3K inhibitor) successfully 
blocked temsirolimus-induced AKT 
phosphorylation. Proliferation assays 
revealed that in a majority of cell lines 
tested, BEZ235 or ZSTK474 combined 
with temsirolimus (1 nM) synergistically 
decreased cell growth compared to cells 
treated with any of the agents alone. 
Our data suggest temsirolimus and 
BEZ235 inhibit different components of 
the AKT/mTOR signaling pathway to 
accomplish synergistic pathway 
inhibition. Specifically, temsirolimus 
partially blocked phosphorylation of 
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mTOR and completely abolished 
phosphorylation of p70S6K and its 
downstream substrate, rS6, at low (1 
nM) concentrations. In contrast, BEZ235 
inhibited 4E-BP1 phosphorylation, 
another substrate for mTOR, whereas 
temsirolimus had no effect on 4E-BP1 
phosphorylation. Furthermore, G0/G1 
cell cycle arrest and up-regulation of 
p27 was observed after combination 
treatment of temsirolimus and BEZ235. 
Strikingly, cell death occurred through 
autophagy and not apoptosis. Finally, 
molecular profiling revealed that 
elevated basal levels of AKT 
phosphorylation and a loss of the tumor 
suppressor PTEN correlated with 
sensitivity to combinatorial treatment.  
 
Conclusions - While previous studies 
have established that endometrial 
cancer cells are responsive to drugs that 
inhibit PI3K or mTOR, we observed a 
novel synergistic effect when the 
specific inhibitors were combined. In 
particular, the mechanism of synergy is 
through blocking two arms of the 
PI3K/mTOR signaling pathways: 
p70S6K and rS6 by temsirolimus with 
high efficacy and AKT and 4E-BP1 by 
BEZ235.  Combined inhibition of mTOR 
and PI3K is necessary for therapeutic 
efficacy to abrogate the increased 
signaling through AKT that occurs with 
mTOR inhibition alone.  Loss of PTEN 
and baseline AKT phosphorylation 
appeared to be the most sensitive 
predictors for response to the 
PI3K/mTOR inhibitor combination 
therapy. 
 
 
